Retatrutide cost: projected pricing and how access typically evolves

All retatrutide pricing on this page is projected based on analogous GLP-1 launches. Real numbers only become available at approval. This page is informational and not financial or medical advice.

Lilly has demonstrated through Zepbound the willingness to maintain a relatively stable list price while opening lower self-pay channels (the LillyDirect vials program brought entry-level Zepbound to the $349–$549 range for self-paying patients). The retatrutide rollout is most likely to follow a similar two-tier pattern.

The likely premium over Zepbound reflects retatrutide's larger trial weight-loss effect. A premium of 10–30% on list price would put retatrutide in the ~$1,200 to $1,400 per month range. A direct-to-consumer self-pay tier could plausibly land in the $500 to $800 per month range, depending on dose and program structure.

These are projections informed by industry coverage, not announcements. Real numbers will be set by Lilly and disclosed at or near launch.

• Insurance via primary care. The lowest out-of-pocket option if insurance covers the indication. Coverage for obesity is uneven; for diabetes it is broad.
• Manufacturer direct-to-consumer self-pay. Programs like LillyDirect offer reduced cash-pay pricing without insurance, generally for specific dose presentations.
• Telehealth platforms. Platforms (Hims, Ro, Henry Meds, Mochi, Sequence, etc.) prescribe approved GLP-1 drugs for eligible patients, often bundling clinical visits with pharmacy fulfillment for a monthly subscription.
• Compounding pharmacies. A subset of pharmacies have compounded semaglutide and tirzepatide under specific FDA frameworks. Whether retatrutide will be compounded similarly is uncertain and depends on regulatory conditions at launch.

Wegovy launched in 2021 and Zepbound in late 2023. Both took well over a year to develop meaningful US commercial-payer coverage for the chronic-weight-management indication, and many plans still exclude obesity drugs entirely as of 2026. Medicare statute generally excludes obesity-only indications, though legislative and regulatory pressure to revisit this has been building.

For type 2 diabetes indications, retatrutide is more likely to get faster commercial-payer coverage given the precedent set by Mounjaro and Ozempic.

Wegovy and Zepbound are sold at substantially lower prices in the UK, EU, Canada, Australia, and Japan than in the US, often under negotiated single-payer arrangements or reference-pricing frameworks. The same pattern will almost certainly apply to retatrutide.

Cross-border purchasing is heavily regulated. Patients should not import medications from outside their country without clinical and legal guidance.

Retatrutide will be patent-protected for years post-launch. Generic or biosimilar competition is unlikely before the early 2030s at the soonest. Until then, downward price pressure will come primarily from:

• Manufacturer self-pay tiers (already established for Zepbound).
• PBM rebate negotiation as more GLP-1s reach the market.
• Competitive launches — there are several Phase 3 obesity drugs in development that could pressure pricing if they approve in similar timeframes.
• Possible legislative action on Medicare obesity coverage, which would substantially expand the addressable market.